Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO) (HW794036)

Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO)
Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHW794036
Descripción
Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO) (HW794036) is a human monoclonal antibody detecting Flt-3/Flk-2. Expressed in Mammalian cells.
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG
ID de clonIMC-EB10
Actividad biológica IMC-EB10 (10 ug/mL, 1 h) reduces FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK in Hb1119 and SEM-K2 cells, but activates them in REH and RS411 cells [1]. IMC-EB10 (10 ug/mL, 1 h) activates FLT3 and downstream Akt in ALLs [1]. IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of wild-type FLT3 and ligand-independent constitutive phosphorylation of ITD-mutant FLT3 in EOL-1, EM3, BaF3-ITD and MV4;11 cells [4]. IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of MAPK, AKT and Stat5 in EOL-1, EM3, BaF3-ITD and MV4;11 cells [4]. IMC-EB10 (1.5-100 nM, 1 h) inhibits proliferation of FLT3-Fc-induced proliferation of EOL-1 and BaF3-ITD cells [4]. Western Blot Analysis [1] Cell Line: Hb1119, SEM-K2 cells Concentration: 10 ug/mL Incubation Time: 1 h Result: Reduced FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK. Western Blot Analysis [1] Cell Line: REH, RS411 cells Concentration: 10 ug/mL Incubation Time: 1 h Result: Activated FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK. Western Blot Analysis [1] Cell Line: ALLs Concentration: 10 ug/mL Incubation Time: 1 h Result: Activated FLT3 and downstream Akt. . Blocked the phosphorylation and constitutive phosphorylation of MAPK, inhibited FL-induced phosphorylation of AKT and Stat5 phosphorylation in EOL-1 and BaF3-ITD cells. Parmacokinetics Species Dose Route T 1/2 AUC 0-inf Mice [2] 20 mg/kg i.p. 96 h 38327 ug·h/mL IMC-EB10 (400 ug/10 mg/kg, i.p.
Sistema de expresión Mammalian cells
Objetivo FLT3, Stem cell tyrosine kinase 1, Fetal liver kinase-2, STK-1, STK1, FLK2, CD135, Receptor-type tyrosine-protein kinase FLT3, Fms-like tyrosine kinase 3, FL cytokine receptor, FLK-2, FLT-3
Nivel de endotoxinas < 10 EU/mg
Pureza >95% purity as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P36888
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosIMC-EB10
Fondo

Receptor-type tyrosine-protein kinase FLT3 (CD135) is a ~112 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B.

Referencias 1. Piloto O, et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51 [HW794036]
2. Erik Corcoran, et al. Abstract #2923: Preclinical pharmacokinetic and pharmacodynamic evaluation of the anti-FLT3 monoclonal antibody IMC-EB10. Cancer Res 1 May 2009; 69 (9_Supplement): 2923. [HW794036]
3. David Surguladze, et al. Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody.IMC-EB10 and Methotrexate,Blood,Volume 112, Issue 11,2008,Page 3964,ISSN 0006-4971, [HW794036]
4. Li Y, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood.2004 Aug 15;104(4):1137-44. View More [HW794036]
Nota For research use only. Not suitable for clinical or therapeutic use.
Imágenes
  • Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Anti-Human CD135/FLT3 (IMC-EB10)

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores